Markus Schneider
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Markus Schneider has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Anton Schnitzbauer
Klinik für Chirurgie, Universitätsklinikum Regensburg, Regensburg
1 shared publication - Dirk Walter
Medical Clinic 1, University Hospital Frankfurt Goethe University Frankfurt Frankfurt am Main Germany
1 shared publication - Jan Peveling-Oberhag
Robert-Bosch-Hospital, Stuttgart, Germany
1 shared publication - Martin-Leo Hansmann
Institut für Pathologie, Universitätsklinikum Essen, Essen, Deutschland.
1 shared publication - Ria Winkelmann
Dr. Senckenbergische Institute für Pathologie und Humangenetik an der Universitätsmedizin Frankfurt am Main, Goethe-Universität Frankfurt am Main, Frankfurt am Main, Deutschland
1 shared publication - Stefan Zeuzem
Department of Medicine, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
1 shared publication
Latest Publications
- Open Access
- 9 May 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (5) , 1421
Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital
Immune-modulating therapy is a promising therapy for patients with cholangiocarcinoma (CCA). Microsatellite instability (MSI) might be a favorable predictor for treatment response, but comprehensive data on the prevalence of MSI in CCA are missing. The aim of the current study was to determine the prevalence of MSI in a German tertiary care hospital. Formalin-fixed paraffin-embedded tissue samples, obtained in the study period from 2007 to 2015 from patients with CCA undergoing surgical resection with curative intention at Johann Wolfgang Goethe University hospital, were examined. All samples were investigated immunohistochemically for the presence of MSI (expression of MLH1, PMS2, MSH2, and MSH6) as well as by pentaplex polymerase chain reaction for five quasimonomorphic mononucleotide repeats (BAT-25, BAT-26, NR-21, NR-22, and NR-24). In total, 102 patients were included, presenting intrahepatic (n = 35, 34.3%), perihilar (n = 42, 41.2%), and distal CCA (n = 25, 24.5%). In the immunohistochemical analysis, no loss of expression of DNA repair enzymes was observed. In the PCR-based analysis, one out of 102 patients was found to be MSI-high and one out of 102 was found to be MSI-low. Thus, MSI seems to appear rarely in CCA in Germany. This should be considered when planning immune-modulating therapy trials for patients with CCA.
- 9 May 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (5) , 1421
Open AccessMicrosatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital
Immune-modulating therapy is a promising therapy for patients with cholangiocarcinoma (CCA). Microsatellite instability (MSI) might be a favorable predictor for treatment response, but comprehensive data on the prevalence of MSI in CCA are missing. The aim of the current study was to determine the prevalence of MSI in a German tertiary care hospital. Formalin-fixed paraffin-embedded tissue samples, obtained in the study period from 2007 to 2015 from patients with CCA undergoing surgical resection with curative intention at Johann Wolfgang Goethe University hospital, were examined. All samples were investigated immunohistochemically for the presence of MSI (expression of MLH1, PMS2, MSH2, and MSH6) as well as by pentaplex polymerase chain reaction for five quasimonomorphic mononucleotide repeats (BAT-25, BAT-26, NR-21, NR-22, and NR-24). In total, 102 patients were included, presenting intrahepatic (n = 35, 34.3%), perihilar (n = 42, 41.2%), and distal CCA (n = 25, 24.5%). In the immunohistochemical analysis, no loss of expression of DNA repair enzymes was observed. In the PCR-based analysis, one out of 102 patients was found to be MSI-high and one out of 102 was found to be MSI-low. Thus, MSI seems to appear rarely in CCA in Germany. This should be considered when planning immune-modulating therapy trials for patients with CCA.